Bhutani, Tina
Farberg, Aaron S.
Funding for this research was provided by:
Boehringer Ingelheim Pharmaceuticals, Inc.
Article History
Received: 6 December 2023
Accepted: 17 January 2024
First Online: 16 February 2024
Declarations
:
: Tina Bhutani is a Principal Investigator for trials sponsored by AbbVie, Castle Biosciences, CorEvitas, Dermavant, Galderma, Mindera, and Pfizer; has received research grant funding from Novartis and Regeneron; and has been an advisor for AbbVie, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Janssen, Leo, Novartis, Pfizer, Sun Pharma, and UCB. Aaron S. Farberg is an advisory board member for Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Eli Lilly and Company, Galderma, Incyte, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.